Abstracts
with the PLSF showed a subjective improvement in personal well-being for 65% of the patients after 1 and 2 years of GH treatment. Visits to the doctor in the previous year (from 9.1 ± 1.4 to 3.4 ± 1), days in hospital (from 7.9 ± 2.6 to 1.6 ± 1.5) and days of sick leave (from 26.4 ± 9.8 to 2.2 ± 1.1) significantly decreased during GH therapy. Leisure-time physical activity significantly improved during therapy, whereas satisfaction with physical activity improved only in females. Another gender difference relates to the need for assistance with daily activities, which remained low and constant in males, but seemed to worsen in females. CONCLUSION: Data obtained so far confirm that GH replacement therapy results in a significant long-term improvement of both QoL and general well being and reduction of HCU in the Netherlands. Moreover, after two years of GH therapy both QoL and HCU levels become comparable to the general Dutch population. 
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DEVELOPMENT OF THE GROWTH HORMONE INJECTION QUESTIONNAIRE (GHIQ) FOR ADOLESCENTS
OBJECTIVES:
We report the development of an instrument to assess feelings about self-injection of growth hormone (GH) in adolescents with growth disorders. METHODS: Adolescents (age 11-19 years) in 2 cohorts (UK N = 74 and USA N = 98) completed a 10-item GH questionnaire, as well as health-related quality of life (HRQOL), functional status scales, self-control, and selfesteem scales to assess external validity. The GH and HRQOL questionnaires were repeated in 2-4 weeks. RESULTS: The GH questionnaire contains 10 items in 2 subscales (feelings, injection issues) and a total summary score, with higher scores indicating better acceptance of GH. Internal consistency reliabilities were a = 0.77 Summary Score, a = 0.68 Feelings, and a = 0.78 Injection Issues, with overall test-retest reliability 0.72, and no floor or ceiling effects. Significant summary score correlations with external validity scales were 0.42 HRQOL, 0.34 functional status, 0.25 self-control. Mean summary scores did not differ significantly by cohort, age, gender, or diagnosis (range 4.0-4.4 points). The Injection Issues component was significantly associated with all VSP-AM subscales and total score (all p < 0.01), whereas the Feelings component was significantly correlated with selfesteem, well-being, physical health and the total score (all p < 0.01) as well as with teachers (p < 0.05). CONCLU-SIONS: The GH Injection Questionnaire is both a reliable and valid measure of attitudes for adolescents with growth disorders. It measures different constructs than other instruments. Adolescents who were more comfortable with GH injections had higher HRQOL, functional capacity, and self-control. 
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HEALTHCARE CONSUMPTION, QOL, AND PATIENT-REPORTED OUTCOMES DURING GH REPLACEMENT IN HYPOPITUITARY ADULTS: RESULTS FROM THE GERMAN KIMS COHORT
OBJECTIVES:
The beneficial effects of growth hormone (GH) replacement in patients with GH deficiency (GHD) are now well recognized. Moreover, first evidence that these effects are accompanied by a reduction in the use of healthcare resources has been provided by KIMS, the Pharmacia International Metabolic Database of adult GHD patients receiving GH therapy (Genotropin, Pharmacia Corp.). The aim of the present study was to investigate effects of GH replacement in the German KIMS cohort. METHODS: The analysis was based on 105 patients (65 m, 40 w) with GHD. 1-year follow-up was available from all patients, 2-year follow-up from 60 patients. Statistical analyses were performed with repeated measurements technique. RESULTS: QoL, measured by Nottingham Health Profile (NHP) and QoLAssessment in GHD Adults (QoL-AGHDA) significantly improved after 1 and 2 yrs of GH therapy (NHP distress index: 5.4 ± 4.4 (mean ± SD), 1 yr 3.7 ± 4.2 (p < 0.001), 2 yrs 4.1 ± 5.0; QoL-AGHDA score: 9.4 ± 6.3, 1 yr 6.4 ± 6.1 (p < 0.001), 2 yrs 6.3 ± 6.4 (p < 0.001)). Patientreported outcomes were collected with help of Patient Life Situation Form. 64.0% reported subjective improvement at 1 yr, and 78.9% at 2 yrs (2nd vs. 1st yr: p < 0.05). Visits to the doctor per yr (8.2 ± 6.9, 1 yr 4.8 ± 7.2 (p < 0.001), 2 yrs 3.9 ± 5.0 (p < 0.001)), days in hospital (14.6 ± 20.5, 1 yr 0.9 ± 3.3 (p < 0.001), 2 yrs 0.4 ± 1.8 (p < 0.01)), and days of sick leave (23.8 ± 33.3, 1 yr 1.7 ± 3.5 (p < 0.05), 2 yrs 3.0 ± 4.2 (p < 0.05)) significantly decreased during GH therapy. Males presented a significantly better QoL score in terms of NHP distress index (p < 0.02). Need for assistance with daily activities decreased only in females from 30.8% to 19.1%.
CON-CLUSIONS:
This country specific analysis of the German KIMS cohort confirms significant reduction in the use of healthcare resources as well as significant improvements in QoL and patient reported outcomes during GH replacement in previously untreated adults with GHD. Improvements in QoL seem to be more pronounced in males, whereas females showed a higher reduction of the need for assistance in daily activities.
